What is Modavar Pharmaceuticals?
Modavar Pharmaceuticals is a vertically integrated specialty pharmaceutical company dedicated to the development, manufacturing, and marketing of prescription pharmaceutical products. Operating as a subsidiary of Cadila Pharmaceuticals, Modavar leverages innovative research and advanced manufacturing processes to deliver affordable, high-quality formulations. The company's operational footprint includes FDA-compliant facilities in both the U.S. and India, which not only support its internal product pipeline but also provide contract manufacturing services to other pharmaceutical entities. Modavar's core mission revolves around the discovery and commercialization of pharmaceutical products designed for the prevention, diagnosis, alleviation, and cure of diseases.
How much funding has Modavar Pharmaceuticals raised?
Modavar Pharmaceuticals has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Modavar Pharmaceuticals
PPP
Public-Private Partnership
What's next for Modavar Pharmaceuticals?
The recent major strategic investment signals a pivotal moment for Modavar Pharmaceuticals, indicating a strong market confidence in its late-stage development and commercialization strategies. This capital infusion is expected to accelerate the expansion of its product portfolio, enhance manufacturing capabilities, and potentially fuel further research and development initiatives. As a vertically integrated entity with a focus on affordable, quality formulations, Modavar is well-positioned to capitalize on market opportunities and solidify its competitive advantage in the specialty pharmaceutical landscape.
See full Modavar Pharmaceuticals company page
